≡ Risteys
R13

Documentation Changelog GitHub Contact & Feedback

Benign neoplasm: Nasopharynx

DOID Endpoint Browser PheWeb

CD2_BENIGN_NASOPHARYNX

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519972

1. Apply sex-specific rule

None

519972

2. Check conditions

None

519972

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — D10.6&
  • Hospital discharge: ICD-9 — 2107
  • Hospital discharge: ICD-8 — 2107
  • Cause of death: ICD-10 — D10.6&
  • Cause of death: ICD-9 — 2107
  • Cause of death: ICD-8 — 2107

2 out of 7 registries used, show all original rules.

321

4. Check minimum number of events

None

321

5. Include endpoints

None

321

6. Filter based on genotype QC (FinnGen only)

307

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
D10
Name in latin
Neoplasma benignum nasopharyngis

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 1716 784 921
Only index persons 1545 733 812
Unadjusted period prevalence (%)
Whole population 0.02 0.02 0.03
Only index persons 0.03 0.03 0.03
Median age at first event (years)
Whole population 52.07 54.78 49.75
Only index persons 51.34 54.20 48.77

-FinnGen-

Key figures

All Female Male
Number of individuals 307 154 153
Unadjusted period prevalence (%) 0.06 0.05 0.07
Median age at first event (years) 56.68 54.88 58.49

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
321
Matched controls
3210
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D10.6
ICD-10 Finland
Benign neoplasm: Nasopharynx
4503599627370496.0
307.7
290
*
UDH02
NOMESCO Finland
Rhinopharyngoscopy
13.4
95.9
108
117
EMA30
NOMESCO Finland
Biopsy of rhinopharynx
425.8
69.4
67
*
EMB30
NOMESCO Finland
Adenotomy
20.8
47.2
37
20
UDQ12
NOMESCO Finland
Flexible laryngoscopy
6.3
27.0
50
92
DHA10
NOMESCO Finland
Biopsy of cavity of nose
33.9
21.9
28
9
DCA20
NOMESCO Finland
Insertion of ventilating tube through tympanic membrane
9.0
19.5
25
30
21070
ICD-8 Finland
Benign neoplasm of buccal cavity and pharynx, Nasopharynx
+∞
17.9
17
*
2107A
ICD-9 Finland
Benign neoplasm of lip, oral cavity and pharynx, Nasopharynx
+∞
16.8
16
*
H65.3
ICD-10 Finland
Chronic mucoid otitis media
7.3
15.9
24
35
D14.0
ICD-10 Finland
Benign neoplasm: Middle ear, nasal cavity and accessory sinuses
19.6
14.9
22
12
J35.2
ICD-10 Finland
Hypertrophy of adenoids
13.5
14.1
24
19
H65.2
ICD-10 Finland
Chronic serous otitis media
16.0
13.3
21
14
WX408
NOMESCO Finland
General anesthesy, balanced
2.5
13.2
110
547
DM1AD
NOMESCO Finland
CT of paranasal sinuses and face area
5.7
12.0
23
43
ENA10
NOMESCO Finland
Biopsy of pharynx
48.6
12.0
14
*
R01AD09
ATC
mometasone; nasal
2.3
11.7
166
1030
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
2.2
10.5
186
1243
1290
FHL
Epipharyngoscopy
+∞
10.5
10
*
C11.9
ICD-10 Finland
Malignant neoplasm: Nasopharynx, unspecified
+∞
10.5
10
*
DCA10
NOMESCO Finland
Paracentesis of tympanic membrane
10.1
10.4
20
21
UDC00
NOMESCO Finland
Ear microscopy
3.3
10.4
42
140
WX105
NOMESCO Finland
Surface analgesia on skin or mucosa
3.0
9.8
47
174
ENB00
NOMESCO Finland
Excision or exploration of lesion of pharynx
102.9
9.5
10
*
H66.0
ICD-10 Finland
Acute suppurative otitis media
3.3
9.1
36
118
EMB10
NOMESCO Finland
Tonsillectomy
4.4
9.1
23
55
R01BA52
ATC
pseudoephedrine, combinations; oral
2.2
9.0
107
604
J39.2
ICD-10 Finland
Other diseases of pharynx
13.0
9.0
15
12
J33.0
ICD-10 Finland
Polyp of nasal cavity
5.1
9.0
19
39
R01AD08
ATC
fluticasone; nasal
2.1
8.6
104
589
YA1AD
NOMESCO Finland
CT examination of head and neck for dose design of radiotherapy
20.7
8.5
12
6
Z01.1
ICD-10 Finland
Examination of ears and hearing
2.5
8.3
60
274
H92.0
ICD-10 Finland
Otalgia
3.6
8.1
28
84
I63.3
ICD-10 Finland
Cerebral infarction due to thrombosis of cerebral arteries
4.3
8.1
21
51
DM1BD
NOMESCO Finland
Extensive CT of paranasal sinuses and face area
34.3
8.1
10
*
TPH04
NOMESCO Finland
Cathetrisation of vein
2.2
8.0
84
450
J34.2
ICD-10 Finland
Deviated nasal septum
3.3
7.9
30
96
DHB10
NOMESCO Finland
Excision of lesion of internal nose
46.1
7.7
9
*
EP1AE
NOMESCO Finland
Neck ultrasound examination
3.4
7.7
28
87
R04.0
ICD-10 Finland
Epistaxis
3.0
7.6
35
126
H02AB06
ATC
prednisolone; systemic
1.9
7.4
166
1154
H66.9
ICD-10 Finland
Otitis media, unspecified
3.2
7.4
30
100
C11.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of nasopharynx
+∞
7.3
7
*
J44.1
ICD-10 Finland
Chronic obstructive pulmonary disease with acute exacerbation, unspecified
4.1
7.0
19
48
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.9
6.9
159
1109
R51.80
ICD-10 Finland
Headache
2.3
6.8
59
290
EP1DG
NOMESCO Finland
Very extensive examination of soft tissue of neck with high intesity magnet
17.1
6.8
10
6
R21
ICPC
Throat symptom/complaint
2.1
6.6
68
359
A03FA01
ATC
metoclopramide; systemic, rectal
2.0
6.6
81
457
DMB20
NOMESCO Finland
Functional endoscopic opening of maxillary antrum
3.2
6.5
26
86
Z03.89
ICD-10 Finland
Observation for other suspected diseases and conditions
2.3
6.4
51
241
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
2.5
6.4
41
176
WZC00
NOMESCO Finland
Treatment plan or consultation
1.9
6.3
119
774
Z2221
NOMESCO Finland
Medical doctor
1.9
6.3
97
591
J01CA04
ATC
amoxicillin; systemic
2.1
6.3
261
2168
JN5DR
NOMESCO Finland
PET-CT of upper body metabolism
7.9
6.2
13
17
EP1CG
NOMESCO Finland
Extensive MRI examination of soft tissue of neck with high intesity magnet
8.9
6.1
12
14
EN1BD
NOMESCO Finland
Very extensive CT examination of mouth and soft tissues of neck
8.9
6.1
12
14

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
63
242
2.99
12.37
1.5
1.4
—
—
—
0
0
162
1021
2.18
10.66
2.6
2.1
—
—
—
0
0
185
1234
2.18
10.46
7.7
5.9
57.88
57.57
%
0.14
168
1161
187
1255
2.17
10.38
8.2
6.1
27.71
27.43
%
0.13
170
1178
178
1178
2.15
10.17
8.0
6.0
0.72
0.65
%
0.78
161
1094
182
1218
2.14
10.06
8.0
5.9
2.85
2.82
%
0.06
164
1135
182
1223
2.13
9.90
8.8
6.3
8.67
8.57
%
0.18
165
1146
191
1349
2.03
8.60
8.2
6.3
0.20
0.19
e9/l
0.61
167
1193
190
1345
2.01
8.44
7.5
5.9
1.79
1.91
e9/l
0.75
169
1203
186
1309
2.00
8.37
7.4
5.9
0.04
0.04
e9/l
0.78
162
1135
185
1306
1.98
8.18
7.5
5.9
0.60
0.58
e9/l
0.50
161
1132
203
1502
1.96
7.58
10.8
9.7
4.14
4.10
e9/l
0.10
172
1322
173
1230
1.88
7.12
8.8
6.4
—
—
—
0
0
112
729
1.82
5.83
4.1
4.3
—
—
—
0
0
38
170
2.40
5.42
1.2
1.4
—
—
—
0
0
151
1097
1.71
5.24
4.7
4.6
35.14
35.61
g/l
0.49
138
1034
145
1051
1.69
5.02
2.1
2.0
97.48
95.30
pmol/l
0.20
78
542
196
1540
1.70
4.99
5.3
4.8
6.79
6.72
mmol/l
0.19
184
1442
46
234
2.13
4.85
1.8
2.0
329.23
363.78
nmol/l
0.46
39
211
170
1294
1.67
4.82
7.2
6.5
1.21
1.22
mmol/l
0.26
142
1108
158
1182
1.66
4.78
5.9
5.8
1.21
1.22
mmol/l
0.23
146
1087
67
393
1.89
4.75
2.0
1.9
—
—
—
0
0
234
1945
1.75
4.70
4.6
3.8
14.82
14.75
pmol/l
0.16
216
1755
163
1252
1.61
4.28
17.7
14.0
1.29
1.27
inr
0.09
44
387
212
1751
1.62
4.00
6.1
4.3
—
—
—
0
0
78
504
1.72
3.98
5.5
3.8
989.32
253.41
ng/l
0.92
59
395
12
27
4.57
3.97
1.1
1.4
—
—
nmol/l
—
0
0
230
1941
1.65
3.96
5.8
4.1
14.09
12.03
mm/h
1.13
214
1787
14
44
3.28
3.82
2.4
4.0
—
—
—
0
0
53
312
1.84
3.69
2.6
1.7
—
—
—
0
0
93
650
1.61
3.47
8.9
6.9
—
—
—
0
0
11
28
4.03
3.32
1.5
1.0
—
—
—
0
0
22
97
2.36
3.28
2.2
1.7
—
—
—
0
0
12
34
3.63
3.23
1.1
1.4
0.43
0.50
nmol/l
0.33
12
28
113
845
1.52
3.09
2.8
2.3
—
—
—
0
0
11
31
3.64
3.02
1.2
1.4
—
—
—
0
0
11
31
3.64
3.02
1.3
1.1
—
—
—
0
0
9
21
4.38
3.01
1.8
1.2
—
—
—
0
0
152
1213
1.48
3.01
2.9
2.6
—
—
—
0
0
106
786
1.52
3.00
3.4
4.0
7.40
7.40
ph
0.18
22
161
46
278
1.76
2.94
1.4
1.5
—
—
—
0
0
17
71
2.47
2.85
2.8
3.5
—
—
—
0
0
95
698
1.51
2.78
3.3
2.8
325.48
6247.08
umol/l
2.67
87
606
231
2021
1.51
2.77
10.1
7.6
79.96
80.52
u/l
0.05
216
1898
72
499
1.57
2.74
1.7
1.7
1063.64
1220.02
nmol/l
0.68
52
377
47
293
1.71
2.70
2.0
2.9
1.71
1.83
%
0.39
40
265
53
342
1.66
2.69
4.0
4.9
1.00
1.04
mmol/l
0.72
48
318
59
394
1.61
2.61
1.7
1.8
—
—
—
0
0
133
1057
1.44
2.59
2.3
2.3
74.47
75.49
nmol/l
0.16
118
933
50
321
1.66
2.58
1.4
1.3
—
—
—
0
0
78
558
1.53
2.57
1.7
1.8
1.00
1.28
mg/l
0.89
64
433
135
1080
1.43
2.52
2.8
2.6
124.57
126.98
ug/l
0.04
124
984
11
37
3.04
2.51
2.9
2.1
—
—
—
0
0
9
26
3.53
2.50
1.6
1.1
—
—
—
0
0
10
32
3.19
2.45
1.0
1.2
—
—
—
0
0
77
555
1.51
2.44
4.8
3.9
—
—
—
0
0
6
12
5.07
2.41
1.5
1.0
—
—
—
0
0
63
438
1.55
2.35
1.3
1.3
38.19
32.10
iu/ml
0.16
22
156
14
59
2.44
2.32
1.2
1.5
—
—
—
0
0
35
210
1.75
2.31
7.2
8.0
—
—
—
0
0
51
339
1.60
2.30
1.5
1.6
—
—
—
0
0
105
816
1.43
2.25
4.7
3.9
—
—
—
0
0
11
41
2.74
2.23
1.7
1.3
—
—
—
0
0
85
639
1.45
2.17
2.4
2.1
2.60
3.15
mg/l
1.32
68
551
10
36
2.83
2.15
4.3
3.3
62.86
64.09
%
—
10
36
36
223
1.69
2.14
2.2
3.1
71.09
71.75
e9/l
0.05
28
179
49
329
1.58
2.13
1.6
1.4
—
—
—
0
0
33
201
1.72
2.08
2.5
3.3
4.62
4.44
kpa
0.24
33
193
40
258
1.63
2.05
4.7
3.9
—
—
—
0
0
35
219
1.67
2.01
3.7
4.2
1.16
1.02
%
0.16
19
85
30
180
1.74
2.00
1.8
1.8
1.81
1.44
g/l
0.31
25
162
32
196
1.70
1.99
3.5
4.1
0.50
0.66
%
0.31
16
67
195
1707
1.36
1.95
3.7
3.3
45.68
50.56
u/l
0.32
185
1606
51
353
1.53
1.95
1.5
1.3
510.00
492.38
titre
—
8
84
6
16
3.80
1.94
1.2
4.9
13.20
12.09
%
—
6
16
13
58
2.29
1.93
5.0
2.7
—
—
—
0
0
99
780
1.39
1.93
3.9
3.3
80.50
135.73
mg/l
0.28
64
506
23
129
1.84
1.91
10.7
9.8
—
—
—
0
0
57
406
1.49
1.90
2.8
3.0
3.28
1.96
e6/l
0.35
33
224
92
718
1.39
1.89
3.5
3.1
0.21
0.46
e6/l
1.22
67
544
141
1182
1.34
1.84
11.4
9.8
0.00
0.00
e9/l
0.57
116
975
5
12
4.21
1.83
1.2
1.5
—
—
—
0
0
9
35
2.62
1.81
2.6
3.6
—
—
—
0
0
51
360
1.50
1.78
1.7
2.2
20.37
22.37
%
0.57
43
315
15
74
2.08
1.78
1.2
1.2
—
—
—
0
0
103
829
1.36
1.74
4.8
3.8
15.16
9.69
mg/mmol
0.30
68
527
7
24
2.96
1.73
1.7
1.9
—
—
—
0
0
103
830
1.35
1.72
2.7
2.5
60.80
60.70
u/l
0.00
94
768
111
905
1.35
1.72
4.0
3.7
27.66
67.90
e6/l
1.32
78
664
98
786
1.36
1.69
3.6
3.1
19.58
132.08
e6/l
0.78
72
612
31
198
1.63
1.67
3.4
4.4
0.13
0.13
%
0.02
15
63
29
182
1.65
1.67
1.7
2.2
—
—
—
0
0
37
247
1.56
1.67
1.5
1.5
—
—
—
0
0
8
31
2.62
1.67
1.4
1.1
—
—
—
0
0
64
480
1.42
1.64
3.0
3.1
2.47
2.46
mmol/l
0.32
54
427
8
32
2.54
1.60
4.5
3.4
—
—
—
0
0
273
2558
1.45
1.58
22.1
14.6
22.39
23.61
mg/l
0.26
239
2039
98
794
1.34
1.57
3.6
3.1
—
—
—
0
0
48
345
1.46
1.55
1.2
1.2
—
—
—
0
0
20
116
1.77
1.52
4.6
2.8
25.16
24.76
mmol/l
0.37
20
110
41
287
1.49
1.51
9.0
7.6
1.29
1.35
mmol/l
0.04
33
235
23
140
1.69
1.49
1.3
1.3
—
47.64
—
0
9
15
80
1.92
1.47
1.3
1.2
—
—
—
0
0
29
189
1.59
1.46
3.6
4.4
0.08
0.20
%
0.34
13
54
7
28
2.53
1.46
1.0
1.1
—
—
—
0
0
20
118
1.74
1.45
1.3
1.2
—
—
—
0
0
56
420
1.40
1.44
1.3
1.3
37.63
11.90
u/ml
0.60
12
166
5
16
3.16
1.44
1.0
1.3
—
—
—
0
0
9
39
2.34
1.44
1.0
1.1
—
26.20
—
0
10
107
889
1.31
1.42
3.2
3.3
2.36
2.36
mmol/l
0.02
89
777
202
1823
1.29
1.41
4.5
4.0
—
—
—
0
0
22
135
1.68
1.40
3.8
3.8
—
—
—
0
0
12
60
2.04
1.40
2.0
1.6
—
—
—
0
0
17
97
1.79
1.38
2.1
2.2
153.36
371.71
ug/l
1.62
17
90
31
209
1.53
1.36
5.5
3.8
—
—
—
0
0
10
47
2.16
1.35
1.2
1.5
—
—
—
0
0
267
2512
1.37
1.32
5.3
4.7
6.11
6.00
mmol/l
0.58
241
2285
121
1033
1.28
1.29
4.3
3.9
27.36
41.36
ng/l
1.22
87
748
100
834
1.29
1.28
3.9
3.2
7.40
7.46
mmol/l
0.05
84
698
45
333
1.41
1.26
6.3
6.9
103.93
104.13
mmol/l
0.08
45
333
253
2368
1.32
1.24
6.1
4.6
1.87
2.45
mu/l
0.58
236
2154
29
199
1.50
1.19
2.3
3.4
72.75
82.07
ng/l
0.42
24
178
0
34
0.00
1.16
0.0
1.1
—
—
—
0
0
25
167
1.54
1.16
5.8
4.5
—
—
—
0
0
84
693
1.29
1.16
3.4
3.0
—
—
—
0
0
117
1006
1.26
1.15
4.4
3.6
5.79
5.81
ph
0.02
12
76
281
2681
1.39
1.13
19.3
13.7
—
—
—
0
0
7
30
2.36
1.13
4.3
2.7
—
—
—
0
0
76
622
1.29
1.12
1.6
1.5
20.30
21.12
nmol/l
0.20
62
519
66
530
1.31
1.11
3.4
2.9
524.18
550.49
mosm/kgh2o
0.42
56
457
13
74
1.79
1.08
2.3
2.4
82.90
74.99
ug/min
—
8
43
7
33
2.15
1.06
1.4
1.9
32.71
33.39
pg
—
7
33
13
75
1.76
1.04
1.6
1.6
—
—
—
0
0
65
527
1.29
1.03
2.0
1.5
2.28
2.56
g/l
0.63
40
313
39
293
1.38
1.02
2.4
2.2
130.00
137.11
ug/g
0.06
32
235
7
37
1.91
0.94
5.1
3.1
0.76
0.89
nmol/l
—
7
31
27
193
1.44
0.94
2.9
2.8
3.69
8.81
e9/l
0.99
21
161
38
289
1.36
0.93
3.5
4.3
3.23
46.98
ug/l
0.95
31
241
256
2429
1.27
0.93
7.2
6.0
40.86
40.27
mmol/mol
0.43
237
2255
36
272
1.36
0.92
1.8
1.6
—
—
—
0
0
69
574
1.26
0.89
1.7
1.8
121154328.75
432.93
pmol/l
0.49
52
481
8
42
1.93
0.89
5.1
2.7
1.00
2.29
%
—
8
36
20
136
1.50
0.89
4.8
2.4
—
—
—
0
0
6
30
2.02
0.87
2.0
1.6
1.49
1.07
e9/l
—
6
25
25
179
1.43
0.87
5.2
2.6
5.18
5.14
kpa
0.10
25
174
17
113
1.53
0.84
2.9
2.8
—
—
—
0
0
284
2739
1.32
0.83
24.5
17.0
78.75
77.95
umol/l
0.20
284
2739
92
799
1.21
0.80
2.2
2.2
145.28
212.61
u/l
1.22
87
756
23
165
1.42
0.80
6.5
6.6
23.65
24.88
mmol/l
0.76
23
165
83
714
1.22
0.80
1.7
1.7
1.49
1.43
mmol/l
0.19
61
586
272
2613
1.27
0.79
5.6
5.1
2.64
2.74
mmol/l
0.94
244
2394
23
167
1.41
0.76
4.1
2.6
—
—
—
0
0
9
56
1.62
0.73
2.7
3.9
—
—
—
0
0
5
25
2.02
0.73
2.2
1.6
972.20
525.95
e6/l
—
5
20
7
39
1.81
0.73
2.7
1.3
—
—
—
0
0
11
68
1.64
0.72
1.5
1.2
—
3.43
—
0
10
22
160
1.40
0.72
1.1
1.2
31.74
135.85
iu/ml
—
7
66
16
109
1.49
0.72
1.1
1.1
—
—
—
0
0
5
26
1.94
0.71
1.0
1.1
—
—
—
0
0
5
27
1.86
0.68
1.4
1.6
—
—
—
0
0
5
27
1.86
0.68
2.2
2.6
—
—
—
0
0
64
546
1.22
0.67
5.4
4.2
1.02
1.02
kg/l
—
10
75
5
28
1.80
0.66
1.0
1.2
—
—
—
0
0
139
1273
1.16
0.65
5.0
3.8
0.00
0.00
estimate
-0.00
14
245
16
222
0.71
0.64
1.6
1.4
—
—
—
0
0
8
49
1.65
0.62
1.3
1.5
—
—
—
0
0
137
1257
1.16
0.62
6.3
5.1
0.00
0.00
estimate
-0.00
17
252
25
192
1.33
0.61
1.5
1.3
—
—
—
0
0
275
2663
1.23
0.61
25.4
16.8
3.99
3.98
mmol/l
0.34
269
2598
64
552
1.20
0.61
3.2
2.5
3.86
4.59
e6/l
0.47
56
497
258
2484
1.20
0.61
4.5
4.1
1.33
1.30
mmol/l
0.36
227
2268
0
20
0.00
0.60
0.0
1.3
—
—
—
0
0
283
2751
1.24
0.58
14.8
10.6
24.64
26.13
u/l
1.11
271
2657
17
124
1.39
0.57
2.4
2.3
—
—
—
0
0
15
107
1.42
0.56
3.8
4.2
—
—
—
0
0
36
295
1.25
0.56
1.3
1.3
—
—
—
0
0
77
684
1.17
0.53
1.3
1.4
—
—
—
0
0
6
40
1.51
0.52
1.3
1.7
84.43
90.14
%
—
6
40
6
40
1.51
0.52
1.7
1.3
—
—
—
0
0
135
1252
1.14
0.50
4.8
3.8
0.00
0.00
estimate
0.50
19
269
19
145
1.33
0.50
1.7
1.2
—
—
—
0
0
61
535
1.17
0.49
3.2
2.9
0.76
0.81
ug/l
0.16
39
336
30
245
1.25
0.49
2.4
2.4
6.79
7.92
ug/l
0.18
30
210
11
78
1.42
0.43
2.0
2.5
8.83
13.12
mg/l
1.64
11
73
19
238
0.79
0.42
4.9
3.4
—
—
—
0
0
0
15
0.00
0.41
0.0
2.4
—
—
—
0
0
0
17
0.00
0.41
0.0
1.8
—
9.41
—
0
17
0
17
0.00
0.41
0.0
1.4
—
—
—
0
0
65
720
0.88
0.39
3.6
3.3
—
—
—
0
0
292
2867
1.20
0.39
31.1
21.4
6.81
6.71
e9/l
0.37
286
2789
11
80
1.39
0.39
4.4
5.0
—
—
—
0
0
262
2553
1.14
0.38
5.2
4.6
1.42
1.45
mmol/l
0.60
235
2338
5
36
1.39
0.38
1.4
1.4
—
—
—
0
0
5
36
1.39
0.38
1.4
1.4
—
—
—
0
0
263
2564
1.14
0.38
5.1
4.6
4.55
4.63
mmol/l
0.64
236
2369
18
143
1.27
0.38
1.6
1.5
—
—
—
0
0
5
37
1.36
0.37
1.4
2.2
—
—
—
0
0
63
695
0.88
0.36
5.9
4.1
0.00
0.00
estimate
-0.00
17
250
63
569
1.13
0.36
1.4
1.3
0.85
1.38
u/ml
0.66
11
149
6
42
1.44
0.35
2.5
2.9
—
—
—
0
0
6
86
0.69
0.33
1.2
1.9
—
—
—
0
0
6
87
0.68
0.33
1.2
2.4
—
—
—
0
0
6
87
0.68
0.33
1.2
2.4
—
—
—
0
0
6
87
0.68
0.33
1.2
2.3
—
—
—
0
0
99
924
1.10
0.32
5.2
4.8
3.77
2.65
ug/l
0.39
85
824
13
102
1.29
0.30
1.2
1.1
—
—
—
0
0
291
2866
1.16
0.30
31.4
21.5
39.97
40.34
%
0.49
278
2705
6
82
0.73
0.24
1.0
2.4
—
—
—
0
0
14
115
1.23
0.24
2.4
1.7
—
—
—
0
0
5
38
1.32
0.23
1.6
1.6
—
—
—
0
0
5
39
1.29
0.23
1.0
1.1
—
—
—
0
0
5
42
1.19
0.21
1.0
1.1
—
—
—
0
0
5
42
1.19
0.21
1.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
6.36
—
0
11
0
10
0.00
0.21
0.0
1.3
—
5653.40
—
0
5
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
22
192
1.16
0.21
1.4
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
6
49
1.23
0.20
4.7
3.3
3.07
4.24
e9/l
—
6
49
6
49
1.23
0.20
1.2
1.3
—
—
—
0
0
6
51
1.18
0.19
2.0
2.2
—
—
—
0
0
6
51
1.18
0.19
6.5
3.5
57.33
56.49
%
—
6
51
8
70
1.15
0.16
8.5
2.7
4.58
5.03
kpa
—
8
70
8
70
1.15
0.16
8.5
2.7
8.70
8.20
kpa
—
8
70
13
112
1.17
0.14
1.0
1.1
—
—
—
0
0
21
191
1.11
0.12
2.0
1.7
—
—
—
0
0
11
95
1.16
0.12
15.8
8.7
—
—
—
0
0
25
232
1.08
0.10
1.6
1.5
—
—
—
0
0
5
44
1.14
0.10
6.2
2.0
—
—
—
0
0
6
54
1.11
0.09
1.5
1.1
—
—
—
0
0
6
57
1.05
0.08
1.3
3.8
—
—
—
0
0
7
67
1.05
0.08
1.1
1.1
—
—
—
0
0
6
70
0.85
0.07
1.0
2.6
—
—
—
0
0
6
73
0.82
0.07
1.7
1.3
—
—
—
0
0
95
940
1.02
0.02
3.5
3.0
—
—
—
0
0
15
143
1.05
0.01
1.3
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
8
81
0.99
-0.00
8.5
2.6
7.43
7.42
ph
—
8
73
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
3.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
7
71
0.99
-0.00
1.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
1.79
—
0
5
0
7
0.00
-0.00
0.0
2.0
—
—
—
0
0
5
50
1.00
-0.00
1.0
3.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.8
—
1.12
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
6.02
—
0
5
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
88.00
—
0
5
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0

Mortality – FinRegistry

↥

Association

Association between endpoint CD2_BENIGN_NASOPHARYNX and mortality.

Females

Parameter HR [95% CI] p-value
CD2_BENIGN_NASOPHARYNX 1.468 [1.14, 1.89] 0.003
Birth year 0.988 [0.98, 1.0] 0.01

During the follow-up period (1.1.1998 — 31.12.2019), 99 out of 608 females with CD2_BENIGN_NASOPHARYNX died.

Males

Parameter HR [95% CI] p-value
CD2_BENIGN_NASOPHARYNX 1.524 [1.23, 1.89] < 0.001
Birth year 0.985 [0.98, 0.99] 0.002

During the follow-up period (1.1.1998 — 31.12.2019), 145 out of 638 males with CD2_BENIGN_NASOPHARYNX died.

Mortality risk

Mortality risk for people of age

years, who have CD2_BENIGN_NASOPHARYNX.

N-year risk Females Males
1 0.144% 0.226%
5 0.644% 1.578%
10 1.517% 4.198%
15 2.925% 8.015%
20 5.201% 13.646%

Relationships between endpoints

↥

Index endpoint: CD2_BENIGN_NASOPHARYNX – Benign neoplasm: Nasopharynx

GWS hits: 1

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data